A 16-Person Startup Targets a $20 Billion Market. Its Screen Rejects Most Applicants.

The Screening Process

You apply. The clock starts. Seven days later you have an offer — or you don't. There is no recruiter to charm, no phone screen with HR, no take-home assignment to polish over a weekend. The founders decide, and they decide fast.

Signatur Biosciences runs a three-stage pipeline that compresses the typical ten-day diagnostic-startup median into a week. Stage one is a 30-minute video intro call with a founder or the hiring manager. It tests culture fit and role expectations: whether you understand the problem Signatur is solving and can operate without hand-holding. Stage two is a 60-minute technical deep dive, led by a technical founder or team lead, focused on past projects and problem-solving approach. Stage three is a 45-minute final round with the founding team, covering team fit and offer discussion. No take-home tasks appear at any stage. Theantijobboard.com models this structure from comparable <50-person healthcare companies and confirms the timeline as of October 2026, noting it is a model, not confirmed detail.

The filter points are blunt. At the top of the funnel, a recycled CV gets rejected instantly; founders handling hiring alongside everything else spot generic applications immediately. Theantijobboard.com notes that applications mirroring the job description's language clear automated filters at a materially higher rate. Candidates who lead with their own ambition rather than Signatur's problem, making precision diagnostics accessible on widely available PCR instruments, stall at the intro call. The technical deep dive filters for proof you can ship, not that you can whiteboard; abstract algorithm questions are rare, replaced by scrutiny of what you've built and how you debugged it. The final round, identified as the hardest stage, tests whether your working style aligns with a team that values speed, simplicity, and diversity as operational necessities rather than slogans.

First-party board data shows one live opening as of the past week: a Lab Officer role in Liège, Belgium. Typical applicant volume for healthcare diagnostics roles at this size runs 50–100 in two weeks. The median application receives no response at all; a single follow-up at day five roughly doubles reply rates. Signatur's careers page states the team is "FAST, obsessed with moving fast" and that "the best tools are simple tools," principles that shape every screening decision. The process selects for autonomy and mission alignment because at a small team, there is no margin for passengers.

The Company Context

Signatur Biosciences began as a spinout from the Stevens Group at Imperial College London and the University of Oxford. The company was founded in 2022 by three people: Celestin de Wergifosse, John Goertz, and Dame Molly Stevens, Ph.D. De Wergifosse, recently named to the Forbes Europe 30 Under 30 list for healthcare innovation, serves as CEO. Goertz holds a doctorate. Stevens, a professor and dame, leads a research group spanning both institutions.

The startup entered Y Combinator's Summer 2022 batch, a signal that its approach had passed an early stress test. Y Combinator's directory describes the company in one sentence: "Simple tests for complex diseases." That phrasing captures the core bet. Most molecular diagnostics for complex conditions, breast cancer prognosis for instance, rely on centralized labs, expensive instruments, and weeks of turnaround. Signatur's alternative is a platform called PCRchitectur that condenses multi-biomarker gene expression signatures into a single qPCR reaction. The machines required are already in virtually every biomedical lab on the planet. PCR capacity in the US grew 5,500 percent during the pandemic; in the UK, 3,000 percent. The infrastructure exists. The company's job is to make it useful for a new class of tests.

The lead product, OncoSignatur Breast, is a decentralized qPCR kit for breast cancer prognosis. It is designed to run on standard equipment in local hospital labs, delivering same-day results at a fraction of the $4,000 price tag and three-week wait of the current US-centralized standard. The company says material costs drop up to 20-fold. Clinical validation is the next milestone. Breast cancer is the first indication; the platform is built to expand into other disease areas.

Funding followed the Y Combinator stamp.

A Seed round closed in May 2025, led by The Discovery Lab of IBA alongside Noshaq and the Y Combinator Continuity Fund. The round is earmarked for building and validating OncoSignatur Breast, establishing a dedicated laboratory, and expanding the team. The lab is relocating to Liège, Belgium, a move facilitated by Noshaq, to anchor operations in a growing European biotech ecosystem. Head office remains in London. As of the latest LinkedIn hiring post, the team numbers sixteen across the two sites.

Signatur Biosciences describes its mission plainly: make precision diagnostics accessible globally, starting with breast cancer. The problem it targets is geographic and economic. Prognostic tests that predict relapse risk have transformed treatment decisions, letting many women avoid unnecessary chemotherapy. But access remains a barrier. Samples ship internationally. Results take weeks. Millions of women never get the information in time. The company's founders frame this as a center-of-gravity problem: "Advanced diagnostics shouldn't be gated by geography."

That mission — accessibility through simplification — is not marketing copy. It shapes the technical architecture, the commercial strategy, and the hiring screen. A team of sixteen building a platform for a $20 billion addressable market does not have headcount for passengers. Every role must pull toward the same vector.

The Open Roles

The hiring board tells a clearer story than the job descriptions alone. As of October 2026, Signatur Biosciences shows one live opening on Zero G Talent: a Lab Officer (Liège, Belgium) posted within the past week. The company's own careers page lists a longer roster: Senior Technical Assistant in Liège, plus a string of closed roles that include Scientist, Head of Lab Operations, COO, Clinical Marketing Manager, Research Assistant in New Haven, Quality/Operations, Associate Scientist, and an RA/QA Manager in London. The Regulatory Affairs & Quality Assurance Officer role that dominates the LinkedIn posting (view 4464480912, updated 11 October 2026) is marked closed on third-party aggregators including sponsorjobs.co and gorodeo.app. A Senior Biostatistician position also appears on LinkedIn, posted one month ago with 102 applicants.

The RA/QA Officer role, while closed, remains the most fully documented window into what Signatur screens for. The LinkedIn posting describes it as a hands-on early-career position: "junior candidates are welcome" with roughly one year of relevant experience and ISO 13485 exposure listed as desirable rather than mandatory. Academic, placement, and personal-project examples can demonstrate capability. The posting explicitly targets life-science and engineering profiles over pharmaceutical-career or pharmacy-qualified ones. Day-to-day responsibilities span maintaining document-control trackers, approval status, training records, and onboarding documentation; keeping non-conformity and CAPA records current with escalation of overdue items; supporting supplier qualification records; preparing evidence for internal and external audits; drafting and updating SOPs, work instructions, forms, and templates under the Head of RAQA's review; and supporting validation documentation for quality and laboratory software tools under supervision. The role reports to the Head of RAQA with direct mentoring and review built in.

Two requirements distinguish this posting from a standard junior RAQA listing. First, the regulatory scope: the officer helps define and implement a regulatory strategy embedded in the product development plan, leads FDA and EU pre-submissions and submissions, collaborates with the CSO and scientists on QMS implementation, supports clinical-study design and implementation, and contributes to IVDR quality-system expansion, technical documentation, labelling, and instructions for use, though programme ownership and regulatory approval remain with senior reviewers. Second, the AI fluency requirement: "confident practical use of ChatGPT, ChatGPT Work or Claude Cowork beyond ordinary chatbot conversations: creating projects with appropriate context and instructions, using authorised connectors, and creating or improving reusable skills." The posting demands a proactive mindset toward simplifying and automating repetitive work with AI, coupled with the ability to check results, spot errors, and keep necessary human review in place. Experience with medical devices or IVDs, IVDR/MDR concepts, molecular biology or qPCR workflows is noted as useful; French is a plus; Claude Code, a more developed personal AI stack, coding, and deeper systems integration are flagged as additional strengths, "this is not an AI engineering role."

Compensation for the RA/QA Officer was listed as base salary plus equity, calibrated to experience level, with generous paid time off (three weeks plus approximately one additional week during year-end holidays), potential private medical insurance, and an employee pension scheme. The careers page notes benefits may evolve as the company grows.

The current Lab Officer role in Liège carries less public detail. The Zero G Talent listing confirms the location and recency; the company's careers page lists that role as the only other open technical position. Founders John Goertz and Celestin de Wergifosse have not published detailed specs for the Lab Officer position in the sources reviewed. Candidates should treat the RA/QA Officer posting as the strongest available proxy for the technical bar, the AI-automation expectation, and the regulatory-DNA Signatur is building into every function. Then verify current requirements directly with the hiring team at [email protected].

What Gets You Past

Signatur's screen filters for three things in sequence: can you operate in a regulated diagnostics environment, will you thrive in a remote-first team split between London and Liège, and does the mission, making precision diagnostics accessible, actually drive your decisions. The company is sixteen people as of October 2026, backed by Y Combinator and spun out of Imperial College and Oxford. That size means every hire shapes culture; there is no hiding in a department.

That opening is a Lab Officer (Liège, Belgium) role. The Associate Scientist role posted on LinkedIn asks for 3+ years of molecular biology experience and a background in ISO 13485 / IVD. That combination — wet-lab fluency plus quality-system literacy — is the baseline. Candidates who have only worked in research labs without regulatory exposure tend to stall at the technical screen. Conversely, quality professionals who haven't run qPCR assays themselves struggle to credibly discuss assay development timelines. The sweet spot is someone who has built or transferred assays into a regulated setting, preferably on standard qPCR instruments, because that is exactly what Signatur's platform does: it condenses complex RNA signatures into a single PCR assay that runs on existing hospital equipment.

Remote-first does not mean async-only. The team collaborates across London and Belgium with a small on-site presence in Liège for lab work. Candidates who default to "I'll just Slack it" without proposing concrete overlap hours or travel cadence signal they haven't managed distributed lab operations. The careers page states it plainly: "We are a primarily remote company. You can work from anywhere, literally." But the same page invites unsolicited applications to [email protected], which means the screen also weighs initiative: people who write a tailored note about why breast cancer prognosis, why now, and how their specific background moves the needle.

Mission alignment shows up in how candidates frame trade-offs. Signatur's pitch is simplicity without compromise: "Our tests are designed to seamlessly integrate with standard instruments and workflows already in place in every clinical lab." A candidate who argues for the most sensitive assay regardless of instrument compatibility misses the point. The screen rewards people who have shipped products into resource-constrained settings, such as public hospitals, regional labs, and low- and middle-income markets, because they understand that accessibility is a design constraint, not a marketing line.

Diversity, equity, and inclusion are not a separate rubric; they are baked into the mission. It also states: "A diverse team is crucial to fulfill our mission of making precision diagnostics more accessible to all corners of society. Success without diversity, equity, and inclusion is not only meaningless, it's harder." That sentence does double duty. It frames DEI as a mission requirement: precision diagnostics that serve "all corners of society" need a team that reflects those corners, and it rejects the moral-license framing that lets companies treat diversity as a nice-to-have. In practice, the screen looks for evidence that a candidate has worked across disciplines, geographies, or patient populations. The team spans London and Liège; the founders built the company across borders from day one. A resume that shows only homogeneous environments raises a flag. Underserved patient populations are explicit in the company's messaging: "significantly increasing accessibility, including for underserved patient populations." Candidates who have worked on global health diagnostics, or who have navigated regulatory pathways outside the US and EU (the company lists UKRI, IUK, Wallonia.be, and SBRI as supporters), demonstrate the lived experience that makes DEI operational rather than performative.

Simplicity operates the same way, echoing that principle: ease-of-use is the priority at all levels, whether for tests, management strategy, or molecular architecture. The platform itself condenses a breast cancer signature into a single qPCR reaction that runs on machines already in every biomedical lab. That technical philosophy — reduce complexity without losing clinical utility — shapes how Signatur evaluates candidates. The screen favors people who have stripped a workflow down to its essential steps, who can explain a statistical model to a wet-lab scientist, who have killed a feature because it added friction. Complexity for its own sake is a negative signal.

Speed is explicit: "We are FAST. We are obsessed with moving fast. This is how we can strive as a startup and help more patients." The job postings repeat the requirement: "move fast and take pragmatic shortcuts to validate or invalidate ideas quickly." The screen tests for this by asking candidates to describe a time they shipped something imperfect on purpose, learned from the result, and iterated. Perfectionists who need a full spec before writing code or designing an experiment tend to stall out.

Collective success appears as "We only succeed if we all succeed. Employees are the core of our company. Signatur will only succeed if every employee feels valued, respected, empowered, supported, and able to grow the way they want to." In a sixteen-person team with no statistics function until the Senior Biostatistician role is filled, that principle translates into a screen for low-ego collaboration. The company looks for people who have built a function from zero, documented it so others can use it, and handed it off without gatekeeping. The first statistical hire will "own the discipline" but also "build lightweight, reproducible analysis pipelines and the shared data foundations the laboratory and development teams need to work from one source of truth." That dual mandate, ownership plus enablement, is the screen's collaboration litmus test.

The data-driven and AI-native ambitions sharpen the filter. "We take a data-driven approach to how we work, using data and evidence as a default part of every decision, not an afterthought." The newer posting adds: "We are building towards being an AI-native company, using data and AI as a default part of how we work, not an afterthought." Candidates who treat analytics as a service they provide to "the business" rather than a habit they practice daily do not match the bar. The screen probes for experience building tooling that accelerates the team's own work: "finding where AI genuinely removes effort, and making it usable by the rest of the team."

Flexibility rounds the set, as the careers page notes: the company is primarily remote, allowing work from anywhere. That policy is both a value and a practical screen. The lab officer role sits in Liège; the biostatistician and regulatory roles can be remote. Candidates who need daily in-person presence to function will not thrive in a team that operates asynchronously across time zones. The screen checks for self-directed work habits, clear written communication, and comfort with ambiguity: "comfortable with the pace and ambiguity of an early-stage company."

These values are not independent. Simplicity enables speed. Diversity improves the simplicity decisions. Collective success makes remote work sustainable. Data-driven thinking keeps the mission honest. The screen evaluates the whole cluster, not each value in isolation. A candidate who scores high on speed but low on simplicity will build the wrong thing fast. One who champions diversity but cannot operate remotely will fracture the team. The filter passes people who demonstrate the cluster in concert.

The founders come from bioengineering, not commercial diagnostics. They hire for technical depth first, commercial polish second. A candidate who can articulate how a regulatory strategy accelerates patient access — not just compliance — speaks their language. The same goes for biostatistics: the Senior Biostatistician role needs someone who can design studies that satisfy both FDA and EMA with minimal redundant runs, because every extra study delays the accessibility timeline.

In practice, the candidates who advance share a pattern: they have shipped an IVD product or supported a regulatory submission, they have worked across at least two time zones, and they can explain — without jargon — how their work reduces turnaround time or cost for a lab that does not have a genomics core. That is the screen. Everything else is teachable.

Working in frontier tech? Zero G Talent tracks the openings: see every open Signatur Biosciences role, browse frontier tech jobs, the companies hiring, and the people building the field.